Cargando…
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
BACKGROUND: Oncogenic mutations in BRAF genes are found in approximately 5–10% of colorectal cancers. The majority of BRAF mutations are located within exons 11–15 of the catalytic kinase domains, with BRAF V600E accounting for more than 80% of the observed BRAF mutations. Sensitivity to BRAF- and m...
Autores principales: | Nakai, Chikako, Mimaki, Sachiyo, Matsushima, Koutatsu, Shinozaki, Eiji, Yamazaki, Kentaro, Muro, Kei, Yamaguchi, Kensei, Nishina, Tomohiro, Yuki, Satoshi, Shitara, Kohei, Bando, Hideaki, Suzuki, Yutaka, Akagi, Kiwamu, Nomura, Shogo, Fujii, Satoshi, Sugiyama, Masaya, Nishida, Nao, Mizokami, Masashi, Koh, Yasuhiro, Koshizaka, Takuya, Okada, Hideki, Abe, Yukiko, Ohtsu, Atsushi, Yoshino, Takayuki, Tsuchihara, Katsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119053/ https://www.ncbi.nlm.nih.gov/pubmed/36856908 http://dx.doi.org/10.1007/s10147-023-02318-w |
Ejemplares similares
-
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
por: Shinozaki, Eiji, et al.
Publicado: (2017) -
Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013) -
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
por: Harada, Kazuaki, et al.
Publicado: (2019) -
Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts
por: Suzuki, Ayako, et al.
Publicado: (2013) -
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)